Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02315872 · ClinicalTrials.gov registry record · Phase 3
ACTH for Fatigue in Multiple Sclerosis Patients
A Phase 3 study of Multiple Sclerosis (Relapsing Remitting), sponsored by Providence Health & Services.
- Completed
- Registry status
- Phase 3
- Development phase
- 8
- Enrollment target
- 5
- Study locations
NCT02315872 is a Phase 3 study of Multiple Sclerosis (Relapsing Remitting) that has completed, run by Providence Health & Services. The registered enrollment target is 8 participants, below the 562-participant average among 29 other Multiple Sclerosis (Relapsing Remitting) trials with a reported enrollment target (99% lower). The trial reports 5 study locations across 3 states.
The verdict
NCT02315872, a Phase 3 study of Multiple Sclerosis (Relapsing Remitting), has completed, sponsored by Providence Health & Services.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 8 participants
- Enrollment target
- 5
- Study locations
Study Summary
This is a study of Acthar gel (ACTH) in patients with relapsing multiple sclerosis who are experiencing chronic fatigue.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG ACTH
Study Locations (5)
Oregon
- Providence Medical Group - Medford Neurology - Medford
- Providence St. Vincent Medical Center - Portland
Washington
- Swedish Medical Center - Seattle
- MultiCare Health System -- Institute for Research and Innovation - Tacoma
Alabama
- North Central Neurology Associates, PC - Cullman
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2015-05-22 |
| Est. Completion | 2018-12-13 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02315872
The ClinicalTrials.gov registry entry for NCT02315872 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 562-participant average among 29 other Multiple Sclerosis (Relapsing Remitting) trials with a reported enrollment target (99% lower). The listed sponsor is Providence Health & Services, which has 69 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Multiple Sclerosis (Relapsing Remitting) appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT02315872 reports 5 study locations spanning 3 distinct geographic areas - top geographies include Oregon, Washington, Alabama.
Frequently Asked Questions
What is clinical trial NCT02315872 about?
NCT02315872 is a clinical study titled "ACTH for Fatigue in Multiple Sclerosis Patients". This is a study of Acthar gel (ACTH) in patients with relapsing multiple sclerosis who are experiencing chronic fatigue.
What is the current status of trial NCT02315872?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 8 participants. The study started on 2015-05-22. Estimated completion is 2018-12-13.
What conditions does trial NCT02315872 study?
This clinical trial studies the following conditions: Multiple Sclerosis (Relapsing Remitting).
What interventions are being tested in trial NCT02315872?
The interventions under investigation include: Placebo (DRUG), ACTH (DRUG).
Who is sponsoring clinical trial NCT02315872?
This trial is sponsored by Providence Health & Services, which has 69 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02315872 being conducted?
This trial has 5 study locations across Alabama, Oregon, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Sclerosis (Relapsing Remitting)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study to Evaluate the Effectiveness and Safety of Ozanimod Compared to Fingolimod in Children and Adolescents With Relapsing Remitting Multiple Sclerosis
RECRUITING · Phase 3
-
Study to Evaluate the Efficacy, Safety and Tolerability of IMU-838 in Patients With Relapsing Multiple Sclerosis
ACTIVE NOT RECRUITING · Phase 3
-
A Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 (Peginterferon Beta-1a) in Pediatric Participants for the Treatment of Relapsing-Remitting Multiple Sclerosis
ACTIVE NOT RECRUITING · Phase 3
-
A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT)
COMPLETED · Phase 3
-
A Study to Asses Efficacy, Safety and Tolerability of Monthly Long-acting IM Injection of GA Depot in Subjects With RMS
COMPLETED · Phase 3
-
Motor Learning of Fall Resistant Skills Through Slip and Trip Exposure in Multiple Sclerosis
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.